Clinical Summary:

• Design/Population: The phase 3 frontMIND trial enrolled patients with previously untreated high-risk aggressive B-cell lymphomas, including diffuse large B-cell lymphoma, randomized to tafasitamab plus lenalidomide and R-CHOP or standard R-CHOP. Patients were required to have an IPI score of 3-5 and begin treatment within 28 days of diagnosis.
• Key Outcomes: Tafasitamab plus lenalidomide and R-CHOP reduced the risk of progression or death by 25% compared with R-CHOP alone and significantly improved event-free survival. Benefits were observed across key biologic subtypes, including both germinal center B-cell and activated B-cell disease.
• Clinical Relevance: These findings support tafasitamab plus lenalidomide and R-CHOP as a potential new frontline treatment option for patients with high-risk aggressive B-cell lymphomas.

John Burke, MD, Rocky Mountain Cancer Centers, Denver, Colorado, discusses results from the phase 3 frontMIND trial evaluating tafasitamab plus lenalidomide in combination with R-CHOP for previously untreated high-risk diffuse large B-cell lymphoma. The study enrolled a particularly high-risk patient population and was designed to improve outcomes beyond standard chemoimmunotherapy. 

The investigational regimen significantly improved progression-free survival and event-free survival compared with R-CHOP alone, with consistent benefit across major molecular subtypes and centrally confirmed pathology cohorts. Although hematologic toxicities and febrile neutropenia were more common with tafasitamab plus lenalidomide, the safety profile remained manageable, supporting the regimen as a promising new standard-of-care option for high-risk DLBCL.

These results were presented by Georg Lenz, MD, PhD, University Hospital Münster, Münster, Germany, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. 

Transcript: 

My name is John Burke from Sarah Canon Research Institute at Rocky Mountain Cancer Centers, and I’m here at ASCO talking today about the frontMIND clinical trial. 

frontMIND was a trial for patients with previously untreated diffuse large B-cell lymphoma. What we were looking at was a new combination of a drug called tafasitamab in combination with lenalidomide and R-CHOP. Tafasitamab is a monoclonal antibody targeting a protein called CD19 that is present on B lymphocytes. We know that the combination of tafasitamab plus lenalidomide is synergistic in patients with large B-cell lymphoma.

A previous trial called firstMIND tested the combination of tafasitamab and lenalidomide with R-CHOP and demonstrated that the combination had good efficacy. It was a little more toxic than R-CHOP alone, as would be expected, but the toxicities were manageable in the FirstMIND trial. That background led to the development of this phase 3 trial, frontMIND.

Patients were eligible if they had aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma. In addition, we took steps to ensure this was a higher-risk population. Patients had to have an International Prognostic Index, or IPI, score of 3 to 5, which represents a higher-risk group. Many frontline studies include patients with an IPI score of 2. In addition, patients had to begin treatment within 28 days of their diagnostic biopsy, which also enriched for a higher-risk population because patients with slower-moving disease who could wait longer for treatment were not eligible. Patients had to be between 18 and 80 years of age. So overall, this was a relatively high-risk population.

The design of the trial was that patients were randomly assigned to either the control arm, which was six cycles of R-CHOP chemotherapy, the current standard of care, or the investigational arm of tafasitamab plus lenalidomide plus R-CHOP, also given for six cycles. The primary end point of the study was progression-free survival. Secondary end points included response rate, overall survival, and event-free survival. 

The results showed that the investigational arm had superior progression-free survival. Specifically, the risk of progression or death was reduced by 25% in patients receiving tafasitamab plus lenalidomide plus R-CHOP. In addition, event-free survival was improved in the investigational arm. Overall survival was similar between the two arms at this interim analysis, although there appears to be a trend favoring the tafasitamab plus lenalidomide plus R-CHOP arm.

When we looked at patient subgroups, the progression-free survival benefit appeared to apply broadly across essentially all groups of patients on the study. In contrast to some prior studies, there was no significant difference according to the cell-of-origin subtype of DLBCL. Patients with both germinal center B-cell subtype and activated B-cell subtype appeared to benefit from the investigational treatment.

We also examined patients with centrally confirmed pathology, and in that subset the benefit was maintained. In fact, the magnitude of benefit appeared slightly greater than in the overall intent-to-treat population. Those are really the key efficacy findings. Response rates were fairly similar between the two groups.

The addition of tafasitamab and lenalidomide to R-CHOP did increase toxicity somewhat. There were higher rates of grade 3 or higher adverse events, most of which were cytopenias. There was also a slightly higher rate of febrile neutropenia. Treatment-related mortality was also somewhat higher, about 6% in the tafasitamab arm compared with 4% in the R-CHOP arm. Most of those events were related to COVID-19, as the study was conducted during the pandemic. So despite the increase in toxicity, the regimen was manageable for most patients.

In summary, we found that the investigational arm of tafasitamab plus lenalidomide and R-CHOP improved progression-free survival, with no statistically significant impact on overall survival at this point, and did increase toxicity somewhat compared with R-CHOP alone. 

I think this regimen will likely represent a new treatment option, and potentially a new standard option, for patients with previously untreated high-risk diffuse large B-cell lymphoma.

Source: 

Lenz G, Trněný M, Burke JM, et al. frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Presented at the ASCO Annual Meeting. May 29 - June 2, 2026. Chicago, Illinois. LBA7000.